News

The Determine study, coordinated by researchers at Northwestern University and sponsored by St Jude Medical, is the first study to look at patients who already have had a

The company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace.

The Custom III clinical trial was a 90-patient prospective study to assess the safety and efficacy of the Custom NX drug eluting stent system in patients with up

The AbsorbaTack 5mm absorbable tacks provide strong mesh attachment to the surrounding tissues, while reducing the amount of foreign material remaining in the patient long-term. According to the

The company’s revised new drug application (NDA) includes data from additional pharmacokinetic studies conducted by the company comparing CIP-Tramadol ER to Ultram ER. Subject to FDA acceptance for

The Biostat Disc Augmentation System consists of Biostat Biologx Fibrin Sealant, a human derived, biologic tissue sealant, and a proprietary application system designed to safely deliver the biologic

Akorn-Strides, is a joint venture that was formed in 2005 by Akorn and Strides Arcolab. Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said:

The Nanoset intellectual property acquisition includes over 15 issued patents and a number of patent applications covering various uses of nanomagnetic materials, including magnetic resonance imaging (MRI) image

Break study is a randomized, double-blind, placebo controlled study to assess the effect of six months of oral treatment with 400mg (200mg twice daily) alagebrium versus placebo in